Previous 10 | Next 10 |
An open-label Phase 2 clinical trial evaluating Takeda Pharmaceutical Company's (NYSE: TAK ) maribavir (TAK-620) in patients with cytomegalovirus (CMV) infection after undergoing hematopoietic cell transplant or solid organ transplant showed a more significant treatment effect compared to ...
– From the results of a Phase 2 study, maribavir, an investigational agent that targets a specific CMV protein, may result in the clearance of CMV infections, a condition with potentially fatal complications in transplant patients – Two global Phase 3 trials for mariba...
Thinly traded nano cap Ovid Therapeutics ( OVID +6.7% ) is up on below-average volume on the heels of preliminary results from a Phase 2 open-label extension study evaluating soticlestat (OV925/TAK-935) in patients with rare developmental and epileptic encephalopathies, including Drave...
Members of Big Biopharma are in the green as investors exhale after Senate Majority Leader Mitch McConnell (R-KY) warned House Speaker Nancy Pelosi (D-CA 12th District) that her plan to allow Medicare to negotiate drug prices for at least 25 of the most expensive drugs will be dead on arri...
Also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year Achieved more than double the average pharmaceutical industry sustainability score Demonstrated significant year-over-year growth in score for strategy to improve access to medicines ...
− Takeda UK Ltd. is pleased to announce that NICE has recommended the use of Takhzyro® (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within ...
KemPharm ( KMPH ) investors have finally received the long-awaited news on the licensing status of its ADHD drug candidates KP415 and KP484. The reaction to the stock price was not well received, and this is likely due to a smaller than anticipated upfront payment as well as the fact that th...
Patients are advised to immediately consult their healthcare providers to help ensure safe discontinuation of NATPARA treatment Takeda is working closely with the US Food and Drug Administration (US FDA) to resolve the issue and resume supply as soon as possible OSAKA, Japan , Sept...
This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 08/14/2019. Please visit our " Tracking Larry Robbins’ Glenview Capital Manag...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection Canada NewsWire The Letter of Intent is an important ste...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...
Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill. Takeda’s presentations will spa...